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Introduction: The Ebola virus disease (EVD) outbreak in Nigeria began when an infected diplomat from
Liberia arrived in Lagos, the most populous city in Africa, with subsequent transmission to another large
city.
Methods: First-, second-, and third-generation contacts were traced, monitored, and classified.
Symptomatic contacts were managed at Ebola treatment centers as suspected, probable, and confirmed
EVD cases using standard operating procedures adapted from the World Health Organization EVD
guidelines. Reverse transcription PCR tests confirmed EVD. Socio-demographic, clinical, hospitalization,
and outcome data of the July–September 2014 Nigeria EVD cohort were analyzed.
Results: The median age of the 20 EVD cases was 33 years (interquartile range 26–62 years). More
females (55%), health workers (65%), and persons <40 years old (60%) were infected than males, nonhealth workers, and persons aged 40 years. No EVD case management worker contracted the disease.
Presenting symptoms were fever (85%), fatigue (70%), and diarrhea (65%). Clinical syndromes were
gastroenteritis (45%), hemorrhage (30%), and encephalopathy (15%). The case-fatality rate was 40% and
there was one mental health complication. The average duration from symptom onset to presentation
was 3  2 days among survivors and 5  2 days for non-survivors. The mean duration from symptom onset to
discharge was 15  5 days for survivors and 11  2 days for non-survivors. Mortality was higher in the older
age group, males, and those presenting late.
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Conclusion: The EVD outbreak in Nigeria was characterized by the severe febrile gastroenteritis
syndrome typical of the West African outbreak, better outcomes, rapid containment, and no infection
among EVD care-providers. Early case detection, an effective incident management system, and prompt
case management with on-site mobilization and training of local professionals were key to the outcome.
ß 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Ebola virus disease (EVD) is a zoonotic hemorrhagic fever illness
caused by a filovirus. Since its discovery in Zaire in 1976, human
EVD infections have been rare but repeated among people living in
forest communities of endemic central and east African countries.
The endemic countries are the Democratic Republic of Congo,
Uganda, Sudan, and Gabon. Between 1976 and 2013, only two
countries outside the endemic region recorded Ebola cases. In
1994, an ethnologist was infected by a novel Ebola subtype from a
wild chimpanzee in Côte d’Ivoire.1 In 1996, the predominant Zaire
subtype was implicated in a South African case.2
Although Nigeria and other West African countries have
experienced cases of Lassa and dengue fever, the 2014 Ebola virus
outbreak was the largest viral hemorrhagic fever (VHF) outbreak in
these countries. The Nigeria outbreak began on July 20, 2014 when
an infected Liberian-American diplomatic traveler (the index case)
from neighboring Liberia arrived in Lagos, the commercial capital
of Nigeria and Africa’s most populous city. His entry into Lagos and
subsequent spread of the disease to another large city – Port
Harcourt – marked the first recorded spread of Ebola virus in an
international mega-city or large urban setting. This heightened the
international community’s concern for an exponential increase in
the magnitude of the already devastating West African EVD
outbreak.
The clinical profile of patients affected by EVD has been
documented in previous outbreaks. The incubation period is
between 2 and 21 days, and this is followed by an abrupt
presentation of non-specific symptoms. Initial symptoms may
include fever, headache, abdominal pain, diarrhea, vomiting,
macular rash, etc. Late in the clinical course, there may be
hemorrhagic signs and weight loss. Macular rashes were used in
previous outbreaks to aid the differential diagnosis because
patients who presented with such rashes within 5–7 days of
infection often showed signs of desquamation.3 However, recent
events have highlighted the unpredictability of Ebola virus in
human hosts. For example, the 1996 case in Côte d’Ivoire presented
with a variety of symptoms including prostration, but recovered
after a prolonged illness. This contrasts with a case in a 12-year-old
in Uganda who presented simply with fever and yet quickly
progressed to hemorrhage and death within 3 days of presentation
to a health care facility.4
Much of what is known of Ebola signs and symptoms has come
from outbreaks in which data collection was limited. Other factors
that have contributed to the limited understanding of EVD include
the quick progression of clinical manifestations, as well as the level
of infection prevention and control (IPC) measures needed to
manage or study this disease.
The core case identification process, critical clinical presentations, morbidity patterns, primary clinical management, and
outcomes of a confirmed EVD case cohort in Nigeria, seen during
the successful containment effort during the period July 20–
September 30, 2014, are described herein. This review contributes
to the small but growing EVD presentation and management
information from West Africa, which is of value to clinicians and
public health practitioners.

2. Methods
2.1. Outbreak setting and population
The outbreak occurred in two large West African and Nigeriastate capital cities, namely Lagos and Port Harcourt. Lagos, the
most populous city in Africa, is located in the South West geopolitical region of the country, and Port Harcourt in the South
South geo-political region, with land areas of approximately
3345 and 11 077 km2, respectively. Lagos and Port Harcourt are
complex urban megacities with a combined population of over
23 million people. The two cities host international airports and
seaports, and have witnessed large influxes of people not only from
within Nigeria, but also from neighboring countries, as they serve
as major business, employment, and cultural centers.
Like many metropolises in developing countries, Lagos and Port
Harcourt are crowded cities with many slums. More than 60% of
the population in Lagos live in urban slums, which could pose a
challenge to the containment and control of an infectious disease
outbreak. However, compared to other cities in Nigeria, Lagos and
Port Harcourt are among the State capitals with relatively better
developed public and private health care infrastructure, including
emergency response resources.
One of the main ports of entry into Nigeria is Murtala
Muhammed International Airport in Lagos, which is a major hub
for the West African travel route and other international flights.
This airport is one of the busiest in Africa and was the point of entry
for the Nigeria index EVD case.
2.2. Identification of suspected and confirmed EVD case patients and
their management
All persons who were exposed to the index case were traced and
monitored by the contact tracing team. If they subsequently
became ill, their contacts were also traced, placed under
surveillance, and monitored daily for clinical features of EVD,
especially body temperature (using a self-administered axillary
thermometer). As soon as they reported or were observed to have a
body temperature of 38 8C or had other symptoms meeting the
suspected case definition, such as abdominal pain, diarrhea, or
vomiting, sudden bleeding or bloody diarrhea or blood in the urine,
they were referred to the case management team for evaluation
and subsequent evacuation to the Ebola treatment centre (ETC), in
accordance with the adapted EVD screening and case management
standard operating procedure (SOP). They were then reviewed by a
medical officer and admitted to the suspected case isolation ward if
they met the EVD suspected case definition. Third-generation
contacts were also traced and managed based on the SOP, with
significant outcomes especially in the second city – Port Harcourt.
Two of the three tertiary contacts here had been in direct contact
with a secondary contact, while one had shared only an emergency
care centre facility (room) with the same secondary contact,
implicating a nosocomial transmission (Figure 1 shows the EVD
chain of transmission in Nigeria).
Blood samples were collected from suspected case patients and
these were tested by reverse transcription PCR (RT-PCR) for
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Figure 1. Ebola virus disease chain of transmission in Nigeria, July–September 2014.

filovirus at a World Health Organization (WHO)-accredited VHF
laboratory run by the Lagos University Teaching Hospital and a
European Union-donated mobile PCR laboratory in Port Harcourt manned by staff of the National Lassa Fever Research and
Control Institute of the Specialist Teaching Hospital, Irrua-Edo
State.
Admitted suspected case patients were treated empirically for
malaria, volume and electrolyte requirements (in particular with
supervised oral rehydration solution (ORS) intake or when
necessary parenteral fluid and electrolyte therapy), and other
possible concomitant medical issues such as Gram-negative
bacterial sepsis, when appropriate. Food and vitamin supplementation were provided. Non-steroidal anti-inflammatory medications were avoided.
The standard infection prevention and control practices of
Médecins Sans Frontières (MSF) and the WHO5 were observed, as
in the adapted Nigeria EVD IPC SOP. Those patients with a positive
PCR result for Ebola were classified as EVD-confirmed case
patients. Confirmed case patients were continued in care but
separated from suspected case patients into different isolation
wards. After the initial use of temporary isolation wards during the
first 2 weeks of the outbreak, a pre-existing 40-bed internationalstandard infectious disease facility built for multidrug-resistant
tuberculosis patients was adopted as the ETC in Lagos. A 26-bed
primary healthcare facility was modified and used as the ETC in
Port Harcourt. These facilities allowed adequate separation of
isolation wards for suspected and confirmed EVD cases, as well as
the effective practice of EVD IPC procedures with the guidance of
the WHO and MSF experts.
In accordance with the adapted Nigeria EVD discharge SOP,
discharged patients underwent decontamination and were provided with replacement clothes, footwear, basic personal effects,
and a discharge certificate. Psychosocial support for patients and

families was undertaken during the ETC stay, at discharge, and
post-discharge.
Following the initial paucity of EVD-experienced health workers at the beginning of the outbreak, case management subsequently relied heavily on extensive mobilization and onsite
training of local professionals, including nurses experienced in
the care of VHF patients and other infectious disease patients from
the Irrua Specialist Teaching Hospital, Lagos State Mainland
Hospital, and Lagos University Teaching Hospital, supported by
government resources and technical/material contributions from
the WHO, MSF, United Nations International Children’s Emergency
Fund (UNICEF), US Centers for Disease Control and Prevention
(CDC), and the private sector, effectively coordinated by the
National Ebola Emergency Operations Centre (E-EOC) Case
Management Team. Over 250 local case management team
volunteers consisting of physicians (n = 52), including infectious
disease experts (n = 7) and psychiatrists (n = 3), nurses (n = 50),
laboratory scientists (n = 20), nurse-assistants (n = 18), environmental health officers/technicians (n = 30), psychologists (n = 3),
social workers (n = 10), pharmacists (n = 9), and emergency service
workers (n = 60), were mobilized and trained by the WHO, CDC,
MSF, and local infectious diseases experts coordinated by the EEOC Case Management Team coordinator. Key topics included an
overview of EVD, EVD IPC procedures, basics and demonstrations
of donning and un-donning personal protective equipment (PPE),
and case evacuation, burial, and decontamination procedures, as
well as EVD patient care apprenticeship under the WHO and MSF
EVD clinical care experts.
2.3. Data collection and review methods
A suspected case was a primary, secondary, or tertiary contact
of the index case or any traveler from an EVD-infected country
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with the acute onset of fever, malaise, myalgia, or headache,
followed by vomiting or diarrhea, with or without a maculopapular
rash, pharyngitis, or hemorrhage of unknown predisposing
condition. A probable case was defined as a deceased suspected
case (where it had not been possible to collect a specimen for
laboratory confirmation) with an epidemiological link to a
confirmed case. A confirmed EVD case was defined as a suspected
case with laboratory-confirmed diagnostic evidence of an Ebola
virus infection using real-time RT-PCR in Nigeria during the period
July 20 to September 30, 2014.
ETC case management procedures and the clinical and
laboratory data of all confirmed and probable EVD cases identified
during the period July 20 to September 30, 2014 (2014 EVD cohort)
were reviewed by qualified medical professionals in the case
management team. Socio-demographic (age, sex, occupation, city
of residence), clinical (respiratory rate, pulse rate, blood pressure,
presenting symptoms, signs, syndromes, outcome), laboratory
(real-time RT-PCR), and administrative data (date of symptom
onset, duration from symptoms to ETC admission or discharge,
length of ETC stay (LOS)), collected with locally designed data tools
(suspect evaluation form, case investigation form, laboratory
request form, laboratory result form, clinical chart abstraction
form, contact tracing interview notes) were abstracted and entered
into a Microsoft Office Excel 2007 spreadsheet (Microsoft Inc.,
Seattle, WA, USA).
The exposure history, presenting symptoms, history of presenting symptoms, course of illness, excerpts of clinical management, and illness outcome of the individual case patients were
abstracted from their medical records or contact tracing interview
notes and summarized as case histories.
2.4. Data analysis
The key socio-demographic, clinical, administrative, and
outcome data expressed as counts, percentages, median with
range or mean  standard deviation were displayed in tables, and
frequency charts as appropriate, and subjected to univariate analysis.
The morbidity pattern was summarized through case histories,
common presenting symptoms, types of clinical syndrome, and ETC
length of stay, and comparisons were made by dichotomized clinical
outcome. The clinical outcome was summarized as one of three
categories: non-survivor, survivor, and survived with complications.
The dichotomized clinical outcome – dead or alive – was compared by
age group, sex, duration from symptoms to ETC admission, and type of
clinical syndrome in bivariate analysis using the Student t-test for
means and the Chi-square test or Fisher’s exact test for proportions.
Statistical significance was ascertained using the 95% confidence
interval (CI), or a two-tailed p-value of <0.05. Epi-Info version 7 (CDC,
Atlanta, GA, USA) was used for all data analyses.
3. Results
The results comprise a summary of the aggregate EVD case
profiles and the transmission chain.
The total number of EVD cases was 20 (19 confirmed and one
probable); these patients had a median age of 33 years (interquartile range 26–66 years). By age group, the highest percentage
of cases (35%) was among those aged 30–39 years and the lowest
(15%) among those aged 40–49 years. Overall, most EVD cases
(60%) were aged <40 years. More cases were found among females
(55%) than males, and among health workers (65%) than nonhealth workers (Table 1). The common clinical signs (Blood
pressure, respiratory rate, pulse rate) and syndromes (hamorrhagic, gastroentric, encephlopathic syndromes) elicited from EVD
case-patients at the time of first presentation to the ETC are
summarized in Table 2.

The index case was a 40-year-old male Liberian-American
diplomat who spread the disease to 13 of the first-generation
contacts. The first reported case among his contacts was a 28year-old female physician. Only two cases occurred among
second-generation contacts in Lagos. Another first-generation
contact, a male protocol officer in Lagos, travelled against medical
advice to another city – Port Harcourt – and was clandestinely
treated by a 42-year-old male physician who acquired the disease
as a second-generation contact and subsequently transmitted the
disease to three of his third-generation contacts. In all, 13 of the
19 secondary cases were among first-generation contacts and
three cases each among second- and third-generation contacts
(Figure 1).
The common presenting symptoms among cases were fever
(85%), fatigue (70%), diarrhea (65%), anorexia (55%), and vomiting
(50%). Bleeding and headache were present in only 35% and 30% of
cases, respectively (Figure 2). Diarrhea, vomiting, and bleeding
occurred in higher proportions among non-survivors, but this
finding was not statistically significant. The mean duration from
symptom onset to ETC admission was longer among nonsurvivors (5  2 days) than survivors (3  2 days), while the mean
duration from symptom onset to discharge was shorter for nonsurvivors (11  4) than survivors (15  5 days) (Table 3). One
survivor had mental health complications, which were managed
successfully by the psychosocial unit. Being male, 40 years old
(older age), and having severe gastroenteritis or encephalopathy as a
complication seemed to be more related with mortality among EVD
cases (Table 4).

Table 1
Socio-demographic characteristics of EVD cases in Nigeria, July–
September 2014 (N = 20)
Characteristics

EVD cases (%)

Age group (years)
<30
30–39
40–49
50
Sex
Male
Female
Occupation
Health worker
Non-health worker

5
7
3
5

(25)
(35)
(15)
(25)

9 (45)
11 (55)
13 (65)
7 (35)

EVD, Ebola virus disease.

Table 2
Clinical features of EVD cases at presentation, Nigeria, July–September 2014
Clinical feature
Signs
Pulse rate (n = 12)
High (>100 beats/min)
Normal (60–100 beats/min)
Low (<60 beats/min)
Respiratory rate (n = 10)
Fast (> 20 beats/min)
Normal (12–20 beats/min)
Slow (<12 beats/min)
Blood pressure (n = 11)
High (systolic > 120 mmHg)
Normal (systolic 90–120 mmHg)
Low (systolic <90 mmHg)
Syndromes (n = 13)
Hemorrhage
Gastroenteritis
Encephalopathy
EVD, Ebola virus disease.

Proportion of confirmed cases (%)

5 (42.7)
6 (50)
1 (8.3)
9 (90)
1 (10)
0 (0)
2 (18.2)
6 (54.5)
3 (27.3)
1 (7.7)
9 (69.2)
3 (23.1)
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Table 3
Characteristics of EVD cases by clinical outcome, Nigeria, July–September 2014
EVD cases

Characteristics

Dead (n = 8)
Age (years), mean  SD
Male
Female
Symptoms
Fever
Positive
Negative
Fatigue
Positive
Negative
Diarrhea
Positive
Negative
Anorexia
Positive
Negative
Vomiting
Positive
Negative
Headache
Positive
Negative
Bleeding
Positive
Negative
Onset of symptoms to admission (days), mean  SD
Onset of symptoms to discharge (days), mean  SD

RR

p-Value

Alive (n = 12)

45.5  10.4
50.5  16.5

34.6  8.2
33.3  8.5

6 (35.3)
2 (66.7)

11 (64.7)
1 (33.3)

6 (42.9)
2 (33.3)

0.06
0.06

0.53

0.54

8 (57.1)
4 (66.7)

1.3

1.0

6 (46.2)
2 (28.6)

7 (53.8)
5 (71.4)

1.6

0.6

2 (18.2)
6 (66.7)

9 (81.8)
3 (33.3)

0.3

0.06

5 (50.0)
3 (30.0)

5 (50.0)
7 (70.0)

1.7

0.6

2 (33.3)
6 (42.9)

4 (66.7)
8 (57.1)

0.8

1.0

4 (66.7)
4 (28.6)
5  2.2
11.3  4.3

2 (33.3)
8 (57.1)
3.4  2.0
15.5  4.9

2.0

0.3
0.07
0.03

EVD, Ebola virus disease; RR, risk ratio.

4. Discussion
The first outbreak of EVD in Nigeria began in the most populous
city of Africa, with subsequent transmission to a second large city,
and reflected mainly a febrile severe gastroenteritis illness with
less of the hemorrhagic syndrome typifying an extension of the
ongoing West African EVD outbreak.6–9 However, Nigeria had
moderate-to-severe clinical syndromes, less intra-city spread, and
a relatively low case-fatality rate compared to the situation in
sister West African countries. This could be because Lagos and Port
Harcourt are among the cities with a relatively more developed
public and private health care infrastructure. This includes
emergency response resources leveraged by the government-led
multi-partner Ebola emergency operations centre, leading to the
early identification and isolation of most cases, with the
deployment of prompt and effective containment measures.
Molecular studies have shown variations in clinical severity
based on the circulating subtype.10 For instance, outbreaks of the
Zaire subtype in Congo (1976), Gabon (2001), and Congo (2007)

had case-fatality rates (CFR) of 88%, 82%, and 71%, respectively.
Sudan subtype outbreaks had lower CFRs of 56% in Sudan (1976)
and 53% in Uganda (2000).2 Although the West African outbreak,
which is now known to be due to a variant of the Zaire subtype, has
shown a modest CFR, the Nigeria outbreak recorded the lowest CFR
so far. Other studies have reported the reasons for the differential
severity in clinical presentation of EVD cases as being due to the
infective subtype11 and variation in immune response, as well as to
a swift outbreak response.4
Suggestions of differential or better immune response capacity
based on socio-economic differences in Nigerian city dwellers
compared to rural dwellers in the case of other West African
countries or previous outbreaks, might be difficult to ascertain.
This moderate-to-severe picture is probably due to early case

Table 4
Key factors related with mortality in EVD confirmed and probable cases, Nigeria,
July–September 2014
RR

95% CI

2 (28.6)
10 (76.9)

3.1

1.0–9.3

4 (44.4)
4 (36.4)

5 (55.6)
7 (63.6)

1.2

0.4–3.6

5 (38.5)
3 (42.9)

8 (61.5)
4 (57.1)

0.9

0.3 –2.7

4 (44.4)
4 (34.4)

5 (55.6)
7 (63.6)

1.2

0.4–3.6

2 (66.7)
6 (35.3)

1 (33.3)
11 (64.7)

1.8

0.6–5.3

Symptoms

Outcome

Fever
Fatigue
Diarrhea
Anorexia
Vomiting
Bleeding
Headache
Arthralgia
Conjunctivitis
Cough
Sore throat
Painful Eyes
0

20

40

60

80

100

Frequency of Symptoms (%)
Figure 2. Frequency of presenting symptoms among Ebola virus disease cases in
Nigeria, July–September 2014.

Age group (years)
40
<40
Sex
Male
Female
Occupation
Health worker
Non-health worker
Syndromes
Gastroenteritis
Positive
Negative
Encephalopathy
Positive
Negative

Dead

Alive

5 (71.4)
3 (23.1)

EVD, Ebola virus disease; RR, relative risk; CI, confidence interval.
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identification, prompt clinical management, mobilization, training,
and engagement of voluntary workers, and effective coordination
of resources driven by the government-led inter-agency incident
management system (IMS). The availability of in-country personnel from the National Centre for Disease Control and National Polio
Eradication Emergency Operations Centre experienced in IMS was
an added advantage. It is plausible that a positive attitude towards
the EVD outbreak response as demonstrated by key public health
sector personnel, the organized private sector, and volunteers from
the public might have contributed to the relatively better
outcomes observed in Nigeria compared to other affected West
African countries. Also, the swift deployment of over 100 trained
and trainee field epidemiologists from the 7-year-old Nigeria field
epidemiology and laboratory training program and other partneragency professional staff to engage in epidemiological and
surveillance activities, especially contact tracing and monitoring
aided by modern information technology innovations, facilitated a
highly sensitive and timely case identification process. The rapid
deployment of the WHO and MSF EVD case management experts,
availability and prompt mobilization of pre-existing public
medical emergency service resources, and adaptable case isolation
facilities with rapid onsite training of local personnel by
international experts further augmented by partners or private
sector material donations, greatly facilitated rapid case isolation
and early case management.
Barring the limitation of a small EVD patient population, this
study showed that the percentage of female cases was marginally
greater than that of male cases, although males seemed to have a
higher mortality, which is different from the findings in Guinea in
201411 and Bundibugyo, Uganda in 2007.12,13 Most cases were less
than 40 years old, while more health workers were infected
compared to non-health workers. Although health workers are
often traditionally infected in EVD outbreaks, they seemed less
likely to die compared to non-health workers in the Nigeria
experience. In addition, the concentration of cases within the
health facilities provided an insight into the effectiveness of barrier
nursing and standard health facility infection control as being
critical ways of mitigating such contagious infectious diseases.
Also, the rather encouraging fact that aside from health workers
who had been in contact with the index case prior to the EVD
diagnosis in Lagos and the unfortunate case of the over-ambitious
physician in Port Harcourt who clandestinely treated a known
contact of the index case, no member of the EVD case management
team contracted the disease in Nigeria, gives credence to the
excellent infection prevention and control measures including
clinical care process management.
Fever, defined as a body temperature above 38 8C, was evident
in 85% of cases. This contrasts with the Bundibugyo outbreak,
where a febrile illness was observed in 100% of cases.12 This
variation might have occurred because post-mortem cases whose
temperature records were not collected during acute infection
were included among those without fever.
While fatigue (70%) and diarrhea (65%) were among the most
prevalent symptoms seen in this outbreak, hemorrhage occurred
in only 30% of cases. The absence of bleeding in most cases once
more underlines the fact that an insistent search for this distinctive
hemorrhagic fever presentation might lead to EVD misdiagnosis.
The pulse rate and blood pressure at time of presentation were
found to be normal in most of the patients; however, the
respiratory rate was elevated in most of the cases. Hence a normal
blood pressure and pulse may not be used to exclude illness in
suspected EVD cases.
The key clinical syndrome observed was a febrile, moderate-tosevere gastroenteritis with consequent fatigue. This syndrome
should alert clinicians to the possibility of EVD in at-risk persons.
However, those presenting with bleeding seemed to have a higher

mortality, hence suggesting that a hemorrhagic syndrome might
be an indicator of EVD severity. The case fatality of 40% observed in
this population is lower than that observed in the other affected
countries in this outbreak, as well as in previous outbreaks. The
reason for this is unclear, but it could potentially be attributed to
rapid contact tracing, early recognition of suspected cases with
prompt isolation based on a dynamic incident management
system, and effective treatment of EVD cases with an emphasis
on aggressive oral rehydration therapy, parenteral replacement
when needed, anti-malarial therapy, antibiotics, good nutrition,
and psychosocial care. Other unrecognized factors or statistical
limitations due to the low number of cases in Nigeria might also be
a possibility. Observations from other outbreaks have also
indicated that prompt identification and effective management
of EVD cases could account for lower case fatality rates.14
The Nigeria EVD outbreak study encountered some limitations,
including incomplete clinical and administrative data due to the
scarcity of case management personnel during the first 2 weeks of
the outbreak, non-availability of routine onsite laboratory tests for
clinical care of EVD patients other than EVD diagnostics, and a
relatively small patient population with insufficient data for robust
comparative analysis. However, the prompt and effective contact
tracing and case management based on the multi-disciplinary IMS
with the relatively better outcomes (including a low CFR, limited
intra-city spread, no infection among EVD care-providers, and
successful management of a mental health complication) compared to similar outbreaks,9–11 provides an additional reference
resource for local and international EVD/VHF outbreak response or
similar public health emergency management. It also reinforces
the need for a robust early warning or surveillance system for EVD
and other VHFs, backed by pre-positioned appropriate human and
material resources, especially at ports of entry.
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